Table 3: Summary of treatment-emergent adverse events.
|
2.5 Million cells/kg |
5 Million cells/kg |
||
System Organ Class (SOC) |
Cell Events (Patients) |
Control Events (Patients) |
Cell Events (Patients) |
Control Events (Patients) |
Treatment Emergent Adverse Events |
43 (5) |
26 (6) |
32 (6) |
13 (6) |
Blood and lymphatic system disorders |
1 (1) |
- |
1 (1) |
- |
Anaemia |
1 (1) |
- |
1 (1) |
- |
Endocrine disorders |
1 (1) |
- |
- |
- |
Adrenal insufficiency |
1 (1) |
- |
- |
- |
Gastrointestinal disorders |
17 (4) |
9 (4) |
10 (4) |
3 (3) |
Constipation |
4 (2) |
2 (1) |
- |
1 (1) |
Vomiting |
1 (1) |
1 (1) |
2 (1) |
1 (1) |
Abdominal pain |
4 (1) |
1 (1) |
1 (1) |
- |
Nausea |
2 (2) |
- |
1 (1) |
- |
Abdominal pain upper |
1 (1) |
- |
2 (1) |
- |
Ascites |
2 (1) |
1 (1) |
- |
- |
Diarrhoea |
- |
1 (1) |
2 (1) |
- |
Haematochezia |
1 (1) |
1 (1) |
- |
- |
Abdominal distension |
- |
- |
1 (1) |
- |
Aphthous stomatitis |
- |
- |
- |
1 (1) |
Gastric ulcer |
- |
1 (1) |
- |
- |
Haematemesis |
- |
- |
1 (1) |
- |
Haemorrhoids |
- |
1 (1) |
- |
- |
Rectal prolapse |
1 (1) |
- |
- |
- |
Stomatitis |
1 (1) |
- |
- |
- |
General disorders and administration site
conditions |
9 (4) |
5 (2) |
3 (3) |
5 (2) |
Pyrexia |
4 (2) |
4 (2) |
1 (1) |
4 (2) |
Oedema peripheral |
2 (2) |
1 (1) |
1 (1) |
1 (1) |
Chest pain |
1 (1) |
- |
- |
- |
Disease progression |
1 (1) |
- |
- |
- |
Fatigue |
- |
- |
1 (1) |
- |
Non-cardiac chest pain |
1 (1) |
- |
- |
- |
Hepatobiliary disorders |
- |
- |
1 (1) |
- |
Hepatic cirrhosis |
- |
- |
1 (1) |
- |
Infections and infestations |
4 (2) |
2 (2) |
7 (4) |
2 (2) |
Nasopharyngitis |
- |
1 (1) |
- |
1 (1) |
Urinary tract infection |
- |
1 (1) |
1 (1) |
- |
Cellulitis |
- |
- |
1 (1) |
- |
Peritonitis bacterial |
2 (1) |
- |
- |
- |
Bacteraemia |
- |
- |
1 (1) |
- |
Bronchopneumonia |
- |
- |
1 (1) |
- |
Herpes virus infection |
1 (1) |
- |
- |
- |
Infectious pleural effusion |
- |
- |
1 (1) |
- |
Pyelonephritis |
- |
- |
1 (1) |
- |
Sepsis |
- |
- |
1 (1) |
- |
Subcutaneous abscess |
- |
- |
- |
1 (1) |
Typhoid fever |
1 (1) |
- |
- |
- |
Investigations |
2 (2) |
3 (1) |
- |
- |
Urine output decreased |
2 (2) |
- |
- |
- |
Blood bilirubin increased |
- |
1 (1) |
- |
- |
International normalized ratio increased |
- |
1 (1) |
- |
- |
Prothrombin time prolonged |
- |
1 (1) |
- |
- |
Metabolism and nutrition disorders |
1 (1) |
2 (2) |
- |
- |
Diabetes mellitus |
- |
2 (2) |
- |
- |
Hyperkalaemia |
1 (1) |
- |
- |
- |
Musculoskeletal and connective tissue disorders |
3 (2) |
1 (1) |
- |
- |
Arthralgia |
2 (1) |
1 (1) |
- |
- |
Muscle spasms |
1 (1) |
- |
- |
- |
Nervous system disorders |
3 (3) |
- |
3 (2) |
2 (1) |
Hepatic encephalopathy |
2 (2) |
- |
3 (2) |
1 (1) |
Loss of consciousness |
- |
- |
- |
1 (1) |
Paraesthesia |
1 (1) |
- |
- |
- |
Psychiatric disorders |
- |
1 (1) |
- |
- |
Abnormal behaviour |
- |
1 (1) |
- |
- |
Insomnia |
- |
- |
- |
- |
Renal and urinary disorders |
1 (1) |
- |
2 (2) |
- |
Haematuria |
- |
- |
1 (1) |
- |
Renal failure |
- |
- |
1 (1) |
- |
Renal failure acute |
1 (1) |
- |
- |
- |
Reproductive system and breast disorders |
- |
1 (1) |
- |
- |
Gynaecomastia |
- |
1 (1) |
- |
- |
Respiratory, thoracic and mediastinal disorders |
1 (1) |
1 (1) |
4 (2) |
1 (1) |
Cough |
- |
1 (1) |
1 (1) |
1 (1) |
Hydrothorax |
- |
- |
1 (1) |
- |
Pleural effusion |
1 (1) |
- |
- |
- |
Pneumonitis |
- |
- |
1 (1) |
- |
Tachypnoea |
- |
- |
1 (1) |
- |
Skin and subcutaneous tissue disorders |
- |
1 (1) |
- |
- |
Acne |
- |
1 (1) |
- |
- |
Eczema |
- |
- |
- |
- |
Vascular disorders |
- |
- |
1 (1) |
- |
Artery dissection |
- |
- |
1 (1) |
- |